Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
![Phase 2 QUILT 88 trial of DAMP inducers combined with IL15 superagonist, N-803 and anti PDL1-t-haNK cell therapy more than doubles historical overall survival with 3rd to 6th line advanced Pancreatic Cancer](https://immunitybio.com/wp-content/uploads/2022/06/asco2022.jpg)
Phase 2 QUILT 88 trial of DAMP inducers combined with IL15 superagonist, N-803 and anti PDL1-t-haNK cell therapy more than doubles historical overall survival with 3rd to 6th line advanced Pancreatic Cancer
![QUILT-88: NANT Pancreatic Cancer Vaccine in 3rd, 4th, & 5th Line Advanced Disease](https://immunitybio.com/wp-content/uploads/2021/06/asco-Gas.jpg)
QUILT-88: NANT Pancreatic Cancer Vaccine in 3rd, 4th, & 5th Line Advanced Disease
![PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations](https://immunitybio.com/wp-content/uploads/2022/01/img-logo-area-344x194-large.png)